Secondary Central Nervous System Lymphoma Clinical Trial
Official title:
A Phase II, Multicenter, Open-label Study to Evaluate the Safety and Efficacy of ICP-022 in Patients With Recurrent/Refractory Central Nervous System Lymphoma and Recurrent/Refractory Secondary Central Nervous System Lymphoma
The phase II clinical study is to investigate the safety, tolerability, efficacy and pharmacokinetics of ICP-022.
Safety, tolerability evaluation, and anti-tumor effects of ICP-022 in Chinese patients with Recurrent/Refractory Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) will be evaluated in approximately 82 subjects. Pharmacokinetics of ICP-022 will be evaluated in approximately 20 subjects . ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04457869 -
A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 2 | |
Recruiting |
NCT05351593 -
Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03964090 -
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
|
Phase 2 | |
Recruiting |
NCT05011045 -
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
|
||
Recruiting |
NCT05256641 -
Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05398224 -
R-MTX-zanbrutinib in Secondary CNS Lymphoma
|
Phase 2 | |
Recruiting |
NCT05485753 -
A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
|
Phase 1/Phase 2 | |
Recruiting |
NCT05681195 -
Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas
|
Phase 2 |